{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:37:04Z","timestamp":1758638224803},"reference-count":114,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","surgpath.theclinics.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Pathology Clinics"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.path.2015.09.008","type":"journal-article","created":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T01:34:05Z","timestamp":1456882445000},"page":"41-54","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas"],"prefix":"10.1016","volume":"9","author":[{"given":"Amir","family":"Behdad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathanael G.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.path.2015.09.008_bib1","series-title":"WHO classification of tumours of the haematopoietic and lymphoid tissues","year":"2008"},{"issue":"1","key":"10.1016\/j.path.2015.09.008_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.path.2015.09.008_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.mayocp.2011.11.007","article-title":"My treatment approach to patients with diffuse large B-cell lymphoma","volume":"87","author":"Armitage","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"14","key":"10.1016\/j.path.2015.09.008_bib4","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.path.2015.09.008_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.path.2015.09.008_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","article-title":"Phase II Study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin\u2019s lymphoma","volume":"19","author":"Vose","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"7877","key":"10.1016\/j.path.2015.09.008_bib7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0140-6736(74)91786-3","article-title":"Classification of non-Hodgkin's lymphomas","volume":"304","author":"Bennett","year":"1974","journal-title":"Lancet"},{"issue":"S8","key":"10.1016\/j.path.2015.09.008_bib8","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/1097-0142(197410)34:8+<1488::AID-CNCR2820340822>3.0.CO;2-C","article-title":"Immunologic characterization of human malignant lymphomas","volume":"34","author":"Lukes","year":"1974","journal-title":"Cancer"},{"issue":"8580","key":"10.1016\/j.path.2015.09.008_bib9","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(88)90367-4","article-title":"Updated kiel classification for lymphomas","volume":"331","author":"Stansfeld","year":"1988","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.path.2015.09.008_bib10","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","article-title":"National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage","volume":"49","year":"1982","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.path.2015.09.008_bib11","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A\u00a0revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.path.2015.09.008_bib12","doi-asserted-by":"crossref","first-page":"7060","DOI":"10.1200\/JCO.2005.15.503","article-title":"Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas","volume":"23","author":"De Paepe","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.path.2015.09.008_bib13","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2010-03-276766","article-title":"Immunoblastic morphology but not the immunohistochemical GCB\/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL","volume":"116","author":"Ott","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.path.2015.09.008_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/PAS.0000000000000319","article-title":"Diffuse large B-cell lymphomas of immunoblastic type are a major reservoir for MYC-IGH translocations","volume":"39","author":"Horn","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.path.2015.09.008_bib15","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/leu.2015.43","article-title":"Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma","volume":"29","author":"Horn","year":"2015","journal-title":"Leukemia"},{"issue":"6769","key":"10.1016\/j.path.2015.09.008_bib16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.path.2015.09.008_bib17","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.path.2015.09.008_bib18","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.1732008100","article-title":"A\u00a0gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma","volume":"100","author":"Wright","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"10.1016\/j.path.2015.09.008_bib19","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.path.2015.09.008_bib20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.path.2015.09.008_bib21","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A\u00a0new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Choi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.path.2015.09.008_bib22","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Meyer","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.path.2015.09.008_bib23","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/leu.2012.83","volume":"26","author":"Visco","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.path.2015.09.008_bib24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2002-04-1286","article-title":"Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma","volume":"101","author":"Colomo","year":"2003","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.path.2015.09.008_bib25","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2007.15.9277","article-title":"Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell\u2013like and non\u2013germinal center B-cell\u2013like subtypes of diffuse large B-cell lymphoma","volume":"26","author":"Fu","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.path.2015.09.008_bib26","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1158\/1078-0432.CCR-13-1482","article-title":"Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies","volume":"19","author":"Coutinho","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.path.2015.09.008_bib27","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1182\/blood-2010-12-322362","article-title":"Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"117","author":"Guti\u00e9rrez-Garc\u00eda","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.path.2015.09.008_bib28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/bjh.12983","article-title":"Molecular subtype classification of formalin-fixed, paraffin-embedded diffuse large B-cell lymphoma samples on the ICEPlex\u00ae system","volume":"167","author":"Collie","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.path.2015.09.008_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/labinvest.2014.136","article-title":"Diffuse large B-cell lymphoma: sub-classification by massive parallel quantitative RT-PCR","volume":"95","author":"Xue","year":"2015","journal-title":"Lab Invest"},{"issue":"10","key":"10.1016\/j.path.2015.09.008_bib30","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1158\/1078-0432.CCR-14-0357","article-title":"Reproducible, quantitative, and flexible molecular subtyping of clinical DLBCL samples using the nanostring nCounter system","volume":"21","author":"Veldman-Jones","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.path.2015.09.008_bib31","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.path.2015.09.008_bib32","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.3109\/10428194.2014.982645","article-title":"Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma","volume":"56","author":"Gang","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.path.2015.09.008_bib33","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3324\/haematol.2011.056531","article-title":"A\u00a0cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype","volume":"97","author":"Wilson","year":"2012","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.path.2015.09.008_bib34","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","article-title":"Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers","volume":"26","author":"Wilson","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.path.2015.09.008_bib35","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"J\u00a0Exp Med"},{"issue":"7277","key":"10.1016\/j.path.2015.09.008_bib36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.path.2015.09.008_bib37","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.path.2015.09.008_bib38","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.path.2015.09.008_bib39","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.path.2015.09.008_bib40","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12172","article-title":"Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression","volume":"160","author":"Zhang","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.path.2015.09.008_bib41","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non\u2013germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.path.2015.09.008_bib42","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S1470-2045(14)70191-3","article-title":"Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial","volume":"15","author":"Vitolo","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.path.2015.09.008_bib43","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.path.2015.09.008_bib44","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.3324\/haematol.2013.085134","article-title":"Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi","volume":"98","author":"Chiappella","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.path.2015.09.008_bib45","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/asheducation-2013.1.575","article-title":"Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification","volume":"2013","author":"Ott","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"10.1016\/j.path.2015.09.008_bib46","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/ni.2418","article-title":"The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers","volume":"13","author":"Calado","year":"2012","journal-title":"Nat Immunol"},{"issue":"17","key":"10.1016\/j.path.2015.09.008_bib47","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.path.2015.09.008_bib48","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.path.2015.09.008_bib49","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1200\/JCO.2010.32.8385","article-title":"The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective","volume":"29","author":"Salaverria","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.path.2015.09.008_bib50","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt's lymphoma","volume":"354","author":"Dave","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.path.2015.09.008_bib51","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","article-title":"A\u00a0biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling","volume":"354","author":"Hummel","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.path.2015.09.008_bib52","first-page":"2133","article-title":"The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome","volume":"9","author":"Barrans","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"33","key":"10.1016\/j.path.2015.09.008_bib53","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1200\/JCO.2009.22.7058","article-title":"Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study","volume":"27","author":"Copie-Bergman","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.path.2015.09.008_bib54","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1056\/NEJM199407143310202","article-title":"Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma","volume":"331","author":"Offit","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.path.2015.09.008_bib55","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1182\/blood.V83.7.1757.1757","article-title":"Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma","volume":"83","author":"Lo Coco","year":"1994","journal-title":"Blood"},{"issue":"1\u20132","key":"10.1016\/j.path.2015.09.008_bib56","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/10428199709068271","article-title":"Significance of rearrangement of the BCL6 gene in B-cell lymphoid neoplasms","volume":"27","author":"Ohno","year":"1997","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.path.2015.09.008_bib57","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1046\/j.1365-2141.2002.03435.x","article-title":"Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma","volume":"117","author":"Barrans","year":"2002","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.path.2015.09.008_bib58","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1182\/blood.V96.8.2907","article-title":"Nonimmunoglobulin (non-Ig)\/BCL6gene fusion in diffuse large B-cell lymphoma results in worse prognosis than Ig\/BCL6","volume":"96","author":"Akasaka","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.path.2015.09.008_bib59","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.path.2015.09.008_bib60","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.path.2015.09.008_bib61","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/PAP.0b013e3182a289f2","article-title":"MYC\/BCL2 double-hit high-grade B-cell lymphoma","volume":"20","author":"Li","year":"2013","journal-title":"Adv Anat Pathol"},{"issue":"4","key":"10.1016\/j.path.2015.09.008_bib62","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/PAS.0000000000000147","article-title":"Clinical significance of MYC expression and\/or \u201chigh-grade\u201d morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study","volume":"38","author":"Cook","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.path.2015.09.008_bib63","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/asheducation-2014.1.90","article-title":"Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC","volume":"2014","author":"Swerdlow","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.path.2015.09.008_bib64","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjh.12343","article-title":"B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases","volume":"162","author":"Perry","year":"2013","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.path.2015.09.008_bib65","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/jclinpath-2011-200015","article-title":"Fluorescence in situ hybridisation analysis of formalin-fixed paraffin-embedded tissue sections in the diagnostic work-up of non-Burkitt high grade B-cell non-Hodgkin's lymphoma: a single centre's experience","volume":"64","author":"Foot","year":"2011","journal-title":"J\u00a0Clin Pathol"},{"issue":"3","key":"10.1016\/j.path.2015.09.008_bib66","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/PAS.0b013e31826cebad","article-title":"Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas","volume":"37","author":"Pillai","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.path.2015.09.008_bib67","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3324\/haematol.2013.086173","article-title":"MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"98","author":"Valera","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.path.2015.09.008_bib68","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3324\/haematol.2013.091827","article-title":"Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma","volume":"99","author":"Aukema","year":"2014","journal-title":"Haematologica"},{"issue":"28","key":"10.1016\/j.path.2015.09.008_bib69","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.path.2015.09.008_bib70","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.path.2015.09.008_bib71","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.path.2015.09.008_bib72","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.path.2015.09.008_bib73","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood.V124.21.395.395","article-title":"Preliminary report of a multicenter prospective phase II study of DA-EPOCH-R in MYC-rearranged aggressive B-cell lymphoma","volume":"124","author":"Dunleavy","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.path.2015.09.008_bib74","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1097\/PAS.0000000000000433","article-title":"MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC\/BCL2 protein double-positive diffuse large B-cell lymphoma","volume":"39","author":"Wang","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.path.2015.09.008_bib75","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/modpathol.2013.214","article-title":"Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP","volume":"27","author":"Tzankov","year":"2014","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.path.2015.09.008_bib76","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/ejh.12212","article-title":"MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC\/BCL2 translocations","volume":"92","author":"Pedersen","year":"2014","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.path.2015.09.008_bib77","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/modpathol.2014.95","article-title":"B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC\/BCL2 double-hit lymphomas","volume":"28","author":"Li","year":"2015","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.path.2015.09.008_bib78","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2559.2008.03076.x","article-title":"MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type","volume":"53","author":"Yoon","year":"2008","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.path.2015.09.008_bib79","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3324\/haematol.2009.012864","article-title":"Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma","volume":"95","author":"Stasik","year":"2010","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.path.2015.09.008_bib80","doi-asserted-by":"crossref","first-page":"e33813","DOI":"10.1371\/journal.pone.0033813","article-title":"Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas","volume":"7","author":"Kluk","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.path.2015.09.008_bib81","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JCO.1994.12.1.149","article-title":"Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases","volume":"12","author":"Tang","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.path.2015.09.008_bib82","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1182\/blood-2002-11-3442","article-title":"Rituximab plus CHOP (R-CHOP) overcomes bcl-2\u2013associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)","volume":"101","author":"Mounier","year":"2003","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.path.2015.09.008_bib83","doi-asserted-by":"crossref","first-page":"7785","DOI":"10.1158\/1078-0432.CCR-11-0267","article-title":"BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab","volume":"17","author":"Iqbal","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.path.2015.09.008_bib84","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0002-9440(10)63284-1","article-title":"BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma","volume":"165","author":"Iqbal","year":"2004","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.path.2015.09.008_bib85","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.12763","article-title":"MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"165","author":"Perry","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.path.2015.09.008_bib86","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/modpathol.2014.140","article-title":"Scoring of MYC protein expression in diffuse large B-cell lymphomas: concordance rate among hematopathologists","volume":"28","author":"Mahmoud","year":"2015","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.path.2015.09.008_bib87","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/sj.leu.2401487","article-title":"Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes","volume":"13","author":"Harada","year":"1999","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.path.2015.09.008_bib88","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1309\/RM1Q-1T0B-WKQB-AF5A","article-title":"De novo CD5+ diffuse large B-cell lymphomas. A heterogeneous group containing an unusual form of splenic lymphoma","volume":"114","author":"Kroft","year":"2000","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.path.2015.09.008_bib89","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1046\/j.1365-2141.1999.01513.x","article-title":"De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome","volume":"105","author":"Yamaguchi","year":"1999","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.path.2015.09.008_bib90","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood.V99.3.815","article-title":"De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients","volume":"99","author":"Yamaguchi","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.path.2015.09.008_bib91","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.18632\/oncotarget.3479","article-title":"Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries","volume":"6","author":"Xu-Monette","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.path.2015.09.008_bib92","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdq627","article-title":"CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab","volume":"22","author":"Miyazaki","year":"2011","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.path.2015.09.008_bib93","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2012-10-461848","article-title":"CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.path.2015.09.008_bib94","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.path.2015.09.008_bib95","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.path.2015.09.008_bib96","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood-2011-01-330795","article-title":"Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults","volume":"118","author":"Salaverria","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.path.2015.09.008_bib97","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1182\/blood-2013-06-507996","article-title":"A\u00a0recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma","volume":"123","author":"Salaverria","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.path.2015.09.008_bib98","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s12032-010-9614-0","article-title":"Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement","volume":"28","author":"Pienkowska-Grela","year":"2011","journal-title":"Med Oncol"},{"issue":"7","key":"10.1016\/j.path.2015.09.008_bib99","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.3324\/haematol.2015.124305","article-title":"Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain\/loss pattern","volume":"100","author":"Ferreiro","year":"2015","journal-title":"Haematologica"},{"issue":"7418","key":"10.1016\/j.path.2015.09.008_bib100","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.path.2015.09.008_bib101","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ng.2469","article-title":"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing","volume":"44","author":"Richter","year":"2012","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.path.2015.09.008_bib102","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.2468","article-title":"The genetic landscape of mutations in Burkitt lymphoma","volume":"44","author":"Love","year":"2012","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.path.2015.09.008_bib103","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/leu.2015.34","article-title":"The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum","volume":"29","author":"Momose","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.path.2015.09.008_bib104","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a014282","article-title":"Oncogenic mechanisms in Burkitt lymphoma","volume":"4","author":"Schmitz","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7457","key":"10.1016\/j.path.2015.09.008_bib105","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.path.2015.09.008_bib106","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.path.2015.09.008_bib107","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","article-title":"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation","volume":"117","author":"Yap","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.path.2015.09.008_bib108","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nchembio.1084","article-title":"A\u00a0selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells","volume":"8","author":"Knutson","year":"2012","journal-title":"Nat Chem Biol"},{"issue":"7427","key":"10.1016\/j.path.2015.09.008_bib109","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.path.2015.09.008_bib110","series-title":"Study of EPZ-6438 formerly known as E7438 (EZH2 histone methyl transferase [HMT] inhibitor) as a single agent in subjects with advanced solid tumors or with B-cell lymphomas","year":"2013"},{"issue":"7247","key":"10.1016\/j.path.2015.09.008_bib111","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.path.2015.09.008_bib112","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood-2008-12-194852","article-title":"TNFAIP3\/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas","volume":"114","author":"Honma","year":"2009","journal-title":"Blood"},{"issue":"5870","key":"10.1016\/j.path.2015.09.008_bib113","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"issue":"7332","key":"10.1016\/j.path.2015.09.008_bib114","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"}],"container-title":["Surgical Pathology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918115001142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918115001142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T10:35:11Z","timestamp":1600252511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875918115001142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1875918115001142"],"URL":"https:\/\/doi.org\/10.1016\/j.path.2015.09.008","relation":{},"ISSN":["1875-9181"],"issn-type":[{"value":"1875-9181","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Surgical Pathology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.path.2015.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}